Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
BUSINESS
AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
Kyowa Hakko Kirin said on March 25 that it has extended its accord with AstraZeneca, granting it exclusive rights to Fasenra (benralizumab) for all indications beyond COPD and asthma in Asia including Japan. The UK firm now has worldwide rights…
To read the full story
Related Article
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- AZ to Commercialize Kyowa Kirin’s COPD Drug in Japan
October 31, 2016
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
BUSINESS
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
- Sumitomo’s Gemtesa Expands Label in US to OAB Patients with BPH
December 25, 2024
- Daiichi, AZ Pull EU Dato-DXd Filing for Lung Cancer
December 25, 2024
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…